Turnkey technical solutions covering Phase I through Phase IV studies, molecular screening, and botanical batch release.
Bridging regulatory drug surveillance, therapeutic label expansion, and industrial-scale CDMO manufacturing.
In modern biopharmaceutical and evidence-based phytopharmaceutical development, the regulatory trajectory does not end with authorization. Phase 4 Clinical Trials—frequently referred to as post-marketing surveillance (PMS), real-world evidence (RWE) programs, or phase IV pharmacovigilance—form the critical empirical bridge between controlled clinical trials and longitudinal patient outcomes in diverse populations.
Unlike pre-approval clinical studies (Phase I–III) which operate under constrained exclusion criteria and rigid protocols, Phase 4 clinical trial manufacturers and suppliers handle the dynamic complexities of real-world clinical usage. This includes detecting low-frequency or delayed adverse drug reactions (ADRs), assessing long-term systemic toxicities, studying drug-herb or drug-drug interactions, and demonstrating comparative effectiveness against existing standards of care.
MedGence (Yineng Pharma) integrates our specialized Contract Research Organization (CRO) infrastructure with state-of-the-art Contract Development and Manufacturing Organization (CDMO) capabilities. Headquartered in Changsha, Hunan, China, our R&D center bridges deep classical formulation science with rigorous modern analytical architectures. With over 14 years of clinical R&D operations, 300+ scientists, and close clinical alliances across 100+ Class III Grade A hospitals and top-tier pharmaceutical entities, we provide global clients with end-to-end ODM Phase 4 trial design, electronic data capture (EDC), centralized bioanalysis, and commercial scale-up.
Years in Specialized Botanical & Pharmaceutical Research
Dedicated Research Scientists, Investigators & Chemists
Classic TCM Formulations Fully Modernized & Standardized
Single-Herb Extract Standards & Process Architectures
Unmatched patient recruitment velocity, high-density hospital networks, and integrated supply chain economics.
Phase 4 studies require multi-thousand patient cohorts. Leveraging China's centralized tertiary healthcare infrastructure, MedGence achieves patient enrollment timelines up to 60% faster than typical Western regional sites, drastically accelerating time-to-data.
Our entrenched collaborative agreements with institutions like Shuguang Hospital (Affiliated with Shanghai University of TCM) and Xiangya Hospital ensure rigorous ICH-GCP compliant clinical execution, institutional review board (IRB) compliance, and standardized biological sampling.
Eliminate transfer delays. As study protocols adjust formulation specs or dosage deliveries based on intermediate Phase 4 real-world data, our in-house pilot plants and collaborative factories seamlessly scale production across capsules, tablets, liquids, and granules.
Adapting clinical post-marketing surveillance to the era of decentralization, AI analytics, and multi-regional harmonization.
Implementation of e-Consent, wearable biosensors, and remote mobile nursing to drive patient retention, improve adherence reporting, and lower attrition over 3-to-5 year post-marketing registries.
Machine learning algorithms mine electronic health records (EHR) in real-time, mapping complex multi-component botanical metabolites against global signal detection databases to flag anomalies instantly.
Methodological designs fully compliant with the latest Good Clinical Practice (GCP) updates, ensuring all clinical registries and safety databases satisfy FDA, EMA, PMDA, and NMPA joint submissions.
Translating real-world patient data into documented scientific dossiers for secondary therapeutic claims, pediatric/geriatric dosing adjustments, and global reimbursement listings.
From botanical drug commercialization to cross-border nutraceutical substantiation.
Characterized by complex multi-target matrices. Phase 4 clinical programs systematically map pharmacokinetic/pharmacodynamic profiles, assessing metabolic stability and long-term therapeutic safety across thousands of varied patients over years.
Navigating stringent regulatory boundaries in North America (FTC/FDA) and Europe (EFSA). Real-world evidence gathered via MedGence provides empirical human substantiate data to substantiate structure-function claims and health endorsements.
China’s hospitals hold unique registrations for proprietary hospital preparations (56 registrations developed by MedGence). Phase 4 studies facilitate their transition into nationwide innovative drug commercialization dossiers.
Criteria applied by multinational pharmaceutical buyers when selecting an ODM Phase 4 CRO/CDMO partner.
Procurement demands validated electronic data capture (EDC), immutable audit trails, strict Role-Based Access Controls (RBAC), and full compliance with ALCOA+ data integrity principles.
Every clinical batch requires chromatographic fingerprinting and standardized reference substances, ensuring test substances match baseline formulations throughout multi-year studies.
Under MedGence's entrusted contract research model, all client formulas, active-ingredient process parameters, and patient biodata remain protected by strict non-disclosure regimes.
Global enterprises demand suppliers capable of transitioning validated Phase 4 findings directly into commercial batch production across GMP solid, liquid, and softgel dosage formats.
Critical inquiries regarding protocol architecture, GCP oversight, bioanalytical standards, and supply chain continuity.
Comprehensive analytical development, clinical execution, and custom CDMO production options.